Grace Therapeutics, Inc. (NasdaqCM: GRCE)
Health Care · Pharmaceuticals · US
$2.08
+0.48% today · -30.3% 1Y
Grace Therapeutics, Inc. (NasdaqCM: GRCE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $43.75M and employs 5 people.
Over the last twelve months the share price has lost 30.3%, trading between 1.79 and 5.18.
Tweenvest scores Grace Therapeutics, Inc. across four factors: quality 44/100, value 76/100. Its strongest factor is value.
GRCE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $43.75M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.20
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- $5.18
- 52-week low
- $1.79
- Avg volume (3M)
- —
- Shares outstanding
- 21.04M
- Employees
- 5
- Next earnings
- —
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
- ISIN
- US00439U1043
- Founded
- 2002
- Listed since
- Feb 7, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Yuyu Pharma, Inc.KOSE: A000220 | $44.98M | ₩3,840.00 | +1.59% |
| Oncoinvent ASAOB: ONCIN | $44.84M | Nkr70.00 | -15.46% |
| Advagene Biopharma Co., Ltd.TPEX: 6709 | $44.48M | NT$23.95 | -0.21% |
| Arovella Therapeutics LimitedASX: ALA | $43.87M | AU$0.05 | +10.64% |
| Entropy Neurodynamics LimitedASX: EX1 | $43.32M | AU$— | — |
| Entropy Neurodynamics LimitedASX: ENP | $43.32M | AU$0.04 | -2.56% |
| Avecho Biotechnology LimitedASX: AVE | $43.14M | AU$0.02 | -20.00% |
| Decibel Cannabis Company Inc.TSXV: DB | $43.14M | CA$1.60 | -4.76% |
Figures last refreshed Oct 11, 2026.